Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 277

Results For "IND"

6623 News Found

Bayer submits NDA to USFDA for elinzanetant for the treatment of VMS associated with menopause
Drug Approval | August 01, 2024

Bayer submits NDA to USFDA for elinzanetant for the treatment of VMS associated with menopause

The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo


American Oncology Institute (AOI) Nagpur conducts two consecutive successful bone marrow transplants
News | July 31, 2024

American Oncology Institute (AOI) Nagpur conducts two consecutive successful bone marrow transplants

Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection


Zydus receives approval from COFEPRIS to market? Mamitra to treat various cancers
Drug Approval | July 31, 2024

Zydus receives approval from COFEPRIS to market? Mamitra to treat various cancers

The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2


Jagat Pharma launches isotine eye gummies for enhanced vision support
News | July 31, 2024

Jagat Pharma launches isotine eye gummies for enhanced vision support

These gummies are specially formulated for both kids and adults to nourish the eyes and promote optimal vision development


GSK’s RSV vaccine ‘Arexvy’ receives positive European Medicines Agency’s  CHMP opinion for adults aged 50-59
Drug Approval | July 30, 2024

GSK’s RSV vaccine ‘Arexvy’ receives positive European Medicines Agency’s CHMP opinion for adults aged 50-59

Decision on EU marketing authorisation for this population expected by September 2024


Dr. Reddy's receives positive CHMP opinion from EMA for its proposed Rituximab biosimilar
Drug Approval | July 30, 2024

Dr. Reddy's receives positive CHMP opinion from EMA for its proposed Rituximab biosimilar

Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance


Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr
News | July 29, 2024

Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024


USFDA completes inspection at Biocon Biologics’ facilities in Bengaluru
News | July 29, 2024

USFDA completes inspection at Biocon Biologics’ facilities in Bengaluru

The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants